Biotech Values

[fid]

Since you follow the space and are aware of the alxn results you also know that the peak ck-mb of 100ng/ml is the most appropriate endpoint and medicure's data shows that it reduces the risk of MI and death when that marker is used.

The phase 2 only had 900 patients and they thought by lowering the endpoint to 50ng/ml they would see more events but it created noise.

but then again I am sure you knew that

1. Was there not more mortality/stroke in the two treatment groups compared to placebo? Cause for concern in a trial to reduce mortality? Thoughts?

2. Any thoughts on the following?

Most studies have found a good correlation between the degree of CK-MB elevation and mortality risk, with higher risk for patients with CK-MB >5 times above the upper normal limit Keep in mind 100ng/ml=20 times upper normal limit

http://circ.ahajournals.org/cgi/content/full/110/6/674?ijkey=ea5469d653d282c26323218cdc99c396cb3b36b....


Two studies to put 100ng/ml in perspective.

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1560125

http://meeting.chestjournal.org/cgi/content/abstract/128/4/266S-c


fid